ASIA-PACIFIC IMMUNOGLOBULIN MARKET FORECAST 2022-2030

 

TABLE OF CONTENTS

1.     RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES

1.2. SCOPE OF STUDY

1.3. METHODOLOGY

1.4. ASSUMPTIONS & LIMITATIONS

2.     EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES

2.2. MARKET OVERVIEW

3.     MARKET DYNAMICS

3.1. KEY DRIVERS

3.1.1. GROWTH IN GERIATRIC POPULATION

3.1.2. PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS

3.1.3. INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES

3.2. KEY RESTRAINTS

3.2.1. HIGH COST OF THERAPY

3.2.2. HIGH RISK OF SIDE EFFECTS

4.     KEY ANALYTICS

4.1. IMPACT OF COVID-19 ON IMMUNOGLOBULIN MARKET

4.2. KEY MARKET TRENDS

4.3. PORTER’S FIVE FORCES ANALYSIS

4.3.1. BUYERS POWER

4.3.2. SUPPLIERS POWER

4.3.3. SUBSTITUTION

4.3.4. NEW ENTRANTS

4.3.5. INDUSTRY RIVALRY

4.4. OPPORTUNITY MATRIX

4.5. VENDOR LANDSCAPE

4.6. KEY BUYING CRITERIA

4.6.1. SOURCE

4.6.2. APPLICATION

4.6.3. EPITOPE

4.6.4. VALIDATION

4.7. REGULATORY FRAMEWORK

5.     MARKET BY PRODUCT

5.1. IGG

5.2. IGA

5.3. IGM

5.4. IGE

5.5. IGD

6.     MARKET BY MODE OF DELIVERY

6.1. INTRAVENOUS IMMUNOGLOBULIN

6.2. SUBCUTANEOUS IMMUNOGLOBULIN

6.3. INTRAMUSCULAR IMMUNOGLOBULIN

7.     MARKET BY APPLICATION

7.1. HYPOGAMMA GLOBULINEMIA

7.2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

7.3. PRIMARY IMMUNODEFICIENCY DISEASES

7.4. MYASTHENIA GRAVIS

7.5. MULTIFOCAL MOTOR NEUROPATHY

7.6. IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

7.7. INFLAMMATORY MYOPATHIES

7.8. SPECIFIC ANTIBODY DEFICIENCY

7.9. GUILLAIN-BARRE SYNDROME

7.10. OTHER APPLICATIONS

8.     MARKET BY DISTRIBUTION CHANNEL

8.1. HOSPITAL PHARMACY

8.2. SPECIALTY PHARMACY

8.3. OTHER DISTRIBUTION CHANNELS

9.     MARKET BY END-USER

9.1. HOSPITALS & CLINICS

9.2. HOMECARE

10. GEOGRAPHICAL ANALYSIS

10.1. ASIA-PACIFIC

10.1.1. MARKET SIZE & ESTIMATES

10.1.2. KEY GROWTH ENABLERS

10.1.3. KEY CHALLENGES

10.1.4. KEY PLAYERS

10.1.5. COUNTRY ANALYSIS

10.1.5.1.    CHINA

10.1.5.2.    JAPAN

10.1.5.3.    INDIA

10.1.5.4.    SOUTH KOREA

10.1.5.5.    INDONESIA

10.1.5.6.    THAILAND

10.1.5.7.    VIETNAM

10.1.5.8.    AUSTRALIA

10.1.5.9.    REST OF ASIA-PACIFIC

11. COMPETITIVE LANDSCAPE

11.1. KEY STRATEGIC DEVELOPMENTS

11.1.1. MERGERS & ACQUISITIONS

11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS

11.1.3. PARTNERSHIPS & AGREEMENTS

11.1.4. BUSINESS EXPANSIONS & DIVESTITURES

11.2. COMPANY PROFILES

11.2.1. ADMA BIOLOGICS

11.2.2. BIO PRODUCTS LABORATORY

11.2.3. BIOTEST AG

11.2.4. CHINA BIOLOGIC PRODUCTS INC

11.2.5. CSL BEHRING

11.2.6. GRIFOLS SA

11.2.7. KAMADA LTD

11.2.8. KEDRION BIOPHARMA

11.2.9. LFB GROUP

11.2.10. OCTAPHARMA AG

11.2.11. PFIZER INC

11.2.12. SANQUIN PLASMA PRODUCTS BV

11.2.13. SHANGHAI RAAS BLOOD PRODUCTS CO LTD

11.2.14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD

11.2.15. TAKEDA PHARMACEUTICAL COMPANY LIMITED

 

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - IMMUNOGLOBULIN

TABLE 2: REGULATORY FRAMEWORK

TABLE 3: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY PRODUCT, HISTORICAL YEARS 2018-2021 (IN $ MILLION)

TABLE 4: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY PRODUCT, FORECAST YEARS 2022-2030 (IN $ MILLION)

TABLE 5: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, HISTORICAL YEARS 2018-2021 (IN $ MILLION)

TABLE 6: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, FORECAST YEARS 2022-2030 (IN $ MILLION)

TABLE 7: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY APPLICATION, HISTORICAL YEARS 2018-2021 (IN $ MILLION)

TABLE 8: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY APPLICATION, FORECAST YEARS 2022-2030 (IN $ MILLION)

TABLE 9: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS 2018-2021 (IN $ MILLION)

TABLE 10: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS 2022-2030 (IN $ MILLION)

TABLE 11: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY END-USER, HISTORICAL YEARS 2018-2021 (IN $ MILLION)

TABLE 12: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY END-USER, FORECAST YEARS 2022-2030 (IN $ MILLION)

TABLE 13: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY, HISTORICAL YEARS 2018-2021 (IN $ MILLION)

TABLE 14: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY, FORECAST YEARS 2022-2030 (IN $ MILLION)

TABLE 15: LEADING PLAYERS OPERATING IN ASIA-PACIFIC IMMUNOGLOBULIN MARKET

TABLE 16: LIST OF MERGERS & ACQUISITIONS

TABLE 17: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 18: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 19: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

 

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: OPPORTUNITY MATRIX

FIGURE 4: VENDOR LANDSCAPE

FIGURE 5: KEY BUYING CRITERIA

FIGURE 6: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2021

FIGURE 7: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IGG, 2022-2030 (IN $ MILLION)

FIGURE 8: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IGA, 2022-2030 (IN $ MILLION)

FIGURE 9: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IGM, 2022-2030 (IN $ MILLION)

FIGURE 10: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IGE, 2022-2030 (IN $ MILLION)

FIGURE 11: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IGD, 2022-2030 (IN $ MILLION)

FIGURE 12: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY MODE OF DELIVERY, IN 2021

FIGURE 13: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY INTRAVENOUS IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)

FIGURE 14: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)

FIGURE 15: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)

FIGURE 16: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2021

FIGURE 17: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2030 (IN $ MILLION)

FIGURE 18: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2030 (IN $ MILLION)

FIGURE 19: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2030 (IN $ MILLION)

FIGURE 20: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2030 (IN $ MILLION)

FIGURE 21: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2030 (IN $ MILLION)

FIGURE 22: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2030 (IN $ MILLION)

FIGURE 23: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2030 (IN $ MILLION)

FIGURE 24: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2030 (IN $ MILLION)

FIGURE 25: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2030 (IN $ MILLION)

FIGURE 26: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2030 (IN $ MILLION)

FIGURE 27: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2021

FIGURE 28: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2030 (IN $ MILLION)

FIGURE 29: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2030 (IN $ MILLION)

FIGURE 30: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY OTHER DISTRIBUTION CHANNELS, 2022-2030 (IN $ MILLION)

FIGURE 31: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021

FIGURE 32: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2030 (IN $ MILLION)

FIGURE 33: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2030 (IN $ MILLION)

FIGURE 34: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 35: CHINA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 36: JAPAN IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 37: INDIA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 38: SOUTH KOREA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 39: INDONESIA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 40: THAILAND IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 41: VIETNAM IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 42: AUSTRALIA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 43: REST OF ASIA-PACIFIC IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

 

KEY FINDINGS

The Asia-Pacific immunoglobulin market is estimated to grow with a CAGR of 7.20% during the forecast period of 2022 to 2030. The market growth of the region is fuelled by the launch of advanced and innovative immunoglobulin products, the rise in the geriatric population, and the increasing incidence of various disease types.

 

Get more Insights into the Asia-Pacific Immunoglobulin Market:

https://inkwoodresearch.com/reports/asia-pacific-immunoglobulin-market/

 

MARKET INSIGHTS

The Asia-Pacific immunoglobulin market growth assessment entails the evaluation of China, South Korea, Indonesia, Vietnam, Japan, India, Australia, Thailand, and Rest of Asia-Pacific. Key players are engaged in the launch and development of innovative immunoglobulin products in India. For example, Cipla, in 2021, launched Roche’s COVID antibody cocktail (Imdevimab and Casirivimab) in the country. It is administered for treating moderate to mild COVID-19 in adults and pediatric patients. Casirivimab, as well as Imdevimab, entail human immunoglobulin G-1 (IgG1) monoclonal antibodies produced by recombinant DNA technology in laboratories.

Conversely, there has been a substantial rise in healthcare expenditure in Indonesia. As a result, patients experiencing various types of immunodeficiency diseases and other rare conditions gain fast and easy access to technologically advanced and novel healthcare facilities. Moreover, this factor not only helps in the effective diagnosis but also facilitates improved treatment for numerous disease types. Therefore, these factors are anticipated to propel the market growth in the Asia-Pacific during the forecast period.

 

COMPETITIVE INSIGHTS

Prominent companies operating in the market include Sichuan Yuanda Shuyang Pharmaceutical Co Ltd, Takeda Pharmaceutical Company Limited, Shanghai RAAS Blood Products Co Ltd, etc.

 

Our report offerings include:

·       Explore key findings of the overall market

·       Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)

·       Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions

·       Market Segmentation cater to a thorough assessment of key segments with their market estimations

·       Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

·       Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.

·       Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.

·       Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

 

SEGMENTATION

1.     ADMA BIOLOGICS

2.     BIO PRODUCTS LABORATORY

3.     BIOTEST AG

4.     CHINA BIOLOGIC PRODUCTS INC

5.     CSL BEHRING

6.     GRIFOLS SA

7.     KAMADA LTD

8.     KEDRION BIOPHARMA

9.     LFB GROUP

10. OCTAPHARMA AG

11. PFIZER INC

12. SANQUIN PLASMA PRODUCTS BV

13. SHANGHAI RAAS BLOOD PRODUCTS CO LTD

14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD

15. TAKEDA PHARMACEUTICAL COMPANY LIMITED